Endonovo Therapeutics (ENDV) Equity Average (2016 - 2023)
Endonovo Therapeutics has reported Equity Average over the past 11 years, most recently at -$22.7 million for Q3 2023.
- Quarterly results put Equity Average at -$22.7 million for Q3 2023, down 17.04% from a year ago — trailing twelve months through Sep 2023 was -$22.7 million (down 17.04% YoY), and the annual figure for FY2022 was -$24.0 million, down 59.06%.
- Equity Average for Q3 2023 was -$22.7 million at Endonovo Therapeutics, up from -$23.4 million in the prior quarter.
- Over the last five years, Equity Average for ENDV hit a ceiling of -$11.5 million in Q1 2019 and a floor of -$28.3 million in Q1 2023.
- Median Equity Average over the past 5 years was -$16.9 million (2022), compared with a mean of -$17.6 million.
- Biggest five-year swings in Equity Average: rose 26.8% in 2020 and later crashed 67.25% in 2023.
- Endonovo Therapeutics' Equity Average stood at -$18.5 million in 2019, then rose by 26.8% to -$13.6 million in 2020, then dropped by 25.27% to -$17.0 million in 2021, then crashed by 52.34% to -$25.9 million in 2022, then grew by 12.39% to -$22.7 million in 2023.
- The last three reported values for Equity Average were -$22.7 million (Q3 2023), -$23.4 million (Q2 2023), and -$28.3 million (Q1 2023) per Business Quant data.